多维度质量改进干预对巴西高心血管风险患者循证治疗处方的影响:BRIDGE心血管预防整群随机临床试验
该整群随机临床试验在巴西40家门诊纳入1619例确诊动脉粥样硬化性血栓性疾病患者,评估多维度质量改进干预(病例管理、审计反馈、教育材料)与常规实践相比能否改善循证治疗处方。结果显示干预组12个月时循证治疗(他汀、抗血小板、ACEI/ARB)全或无处方率显著高于对照组(73.5% vs 58.7%;OR 2.30;95%CI 1.14-4.65),但风险因素控制无差异,心血管死亡、心梗和卒中复合终点无显著差异(HR 0.76;95%CI 0.43-1.34)。
要点
- 多维度质量改进干预可显著提高高心血管风险患者的循证治疗处方率。
- 干预未改善高脂血症、高血压或糖尿病的风险因素控制。
- 干预组吸烟者接受戒烟教育比例显著高于对照组(51.9% vs 18.2%)。
核心结论
- 在巴西高心血管风险患者中,多维度质量改进干预改善了循证治疗的处方。
研究设计与样本
- 研究为2臂整群随机临床试验,纳入巴西40家公立和私立门诊(整群)中确诊动脉粥样硬化性血栓性疾病的患者。
- 患者招募时间为2016年8月至2017年8月,随访至2018年8月,数据分析于2018年9月进行。
- 共纳入1619例患者,其中1029例(63.6%)为男性,平均(SD)年龄65.6(10.5)岁。
主要发现
- 干预组符合条件患者接受循证治疗处方的比例高于对照组(73.5%[515/701] vs 58.7%[493/840];OR 2.30;95%CI 1.14-4.65)。
- 干预组与对照组在风险因素控制(高脂血症、高血压或糖尿病)方面无差异。
- 干预组当前吸烟者接受戒烟教育的比例高于对照组(51.9%[364/701] vs 18.2%[153/840];OR 11.24;95%CI 2.20-57.43)。
- 干预组与对照组心血管死亡、急性心肌梗死和卒中的发生率分别为2.6%和3.4%(HR 0.76;95%CI 0.43-1.34)。
关键数值与推荐
- 主要终点为干预期后12个月时无禁忌证患者中循证治疗(他汀、抗血小板治疗、ACEI或ARB)的全或无处方。
- 干预措施包括病例管理、审计与反馈报告、向医护人员和患者分发教育材料,对照组接受常规实践。
临床怎么用
- 对于高心血管风险患者,可采用病例管理、审计反馈和教育材料等多维度质量改进策略以提高循证治疗处方率。
- 该干预对风险因素控制和临床硬终点的影响仍需进一步研究,临床应用中应结合其他管理措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies have found that patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice. OBJECTIVE: To evaluate whether a multifaceted quality improvement intervention can improve the prescription of evidence-based therapies. DESIGN, SETTING, AND PARTICIPANTS: In this 2-arm cluster randomized clinical trial, patients with established atherothrombotic disease from 40 public and private outpatient clinics (clusters) in Brazil were studied. Patients were recruited from August 2016 to August 2017, with follow-up to August 2018. Data were analyzed in September 2018. INTERVENTIONS: Case management, audit and feedback reports, and distribution of educational materials (to health care professionals and patients) vs routine practice. MAIN OUTCOMES AND MEASURES: The primary end point was prescription of evidence-based therapies (ie, statins, antiplatelet therapy, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) using the all-or-none approach at 12 months after the intervention period in patients without contraindications. RESULTS: Of the 1619 included patients, 1029 (63.6%) were male, 1327 (82.0%) had coronary artery disease (843 [52.1%] with prior acute myocardial infarction), 355 (21.9%) had prior ischemic stroke or transient ischemic attack, and 197 (12.2%) had peripheral vascular disease, and the mean (SD) age was 65.6 (10.5) years. Among randomized clusters, 30 (75%) were cardiology sites, 6 (15%) were primary care units, and 26 (65%) were teaching institutions. Among eligible patients, those in intervention clusters were more likely to receive a prescription of evidence-based therapies than those in control clusters (73.5% [515 of 701] vs 58.7% [493 of 840]; odds ratio, 2.30; 95% CI, 1.14-4.65). There were no differences between the intervention and control groups with regards to risk factor control (ie, hyperlipidemia, hypertension, or diabetes). Rates of education for smoking cessation were higher among current smokers in the intervention group than in the control group (51.9% [364 of 701] vs 18.2% [153 of 840]; odds ratio, 11.24; 95% CI, 2.20-57.43). The rate of cardiovascular mortality, acute myocardial infarction, and stroke was 2.6% for patients from intervention clusters and 3.4% for those in the control group (hazard ratio, 0.76; 95% CI, 0.43-1.34). CONCLUSIONS AND RELEVANCE: Among Brazilian patients at high cardiovascular risk, a quality improvement intervention resulted in improved prescription of evidence-based therapies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02851732.
引用
- Machline-Carrion MJ, Soares RM, Damiani LP, et al. Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 30942842. doi:10.1001/jamacardio.2019.0649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。